StocksMedium•5 November 2026•
1 min read
Agenus Reports Q3 2026 Results and Advances Phase 3 Colon Cancer Trial
Key Facts
1Agenus reported financial results for the third quarter ended September 30, 2026.
2The company highlighted progress in preparing the global Phase 3 ROBBIN trial for colon cancer treatment.
Agenus reported financial results for the third quarter ended September 30, 2026. The company highlighted progress in preparing the global Phase 3 ROBBIN trial for colon cancer treatment, according to a statement released via Business Wire.
AGEN closed at $6.97 on November 4, 2026, with the stock reaching a session high of $7.06 and a low of $6.85. The company continues to focus on its clinical pipeline development, specifically the progress of its BOT+BAL combination therapy.